GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-11-09| Asia-Pacific

Meiji Seika Pharma to Expand CMO Business with India Manufacturing Site

by Tyler Chen
Share To
CEO of Meiji Group, Kazuo Kawamura

On November 8, Japan’s Meiji Seika Pharma invested $20.1 million to build a manufacturing site in India. According to the company, the move will boost the production capacity of its contract manufacturing organization (CMO) business, and also contribute to the Meiji Group 2026 Vision.

To Start Operation in March 2023

 

The facility covers 8,000 square meters and has an annual output of 750 million tablets, 75 million packages, and 4 million bottles. It will be established in a factory currently operated by Adcock Ingram, a joint venture between South Africa’s Adcock Ingram Holdings and a wholly-owned subsidiary of Meiji Seika Pharma, Medreich. In addition, the products manufactured in Adcock Ingram will be distributed to South African, European, and Oceanian markets.

The plant is expected to begin operations in March 2023, the company said.

Part of the Meiji Group 2026 Vision

 

As part of the stage 3 plan in the Meiji Group 2026 Vision, the 2023 Medium-Term Business Plan involved 2 goals, which are integrating business operations of Meiji Seika Pharma and KM Biologics and expanding CMO/CDMO business. The former focuses on strengthening the vaccine business, which includes a Covid-19 vaccine, a DTaP-IPV/Hib vaccine, and a dengue vaccine while the latter aims to enlarge the production and  R&D capacity of CMO/CDMO.

In the 2026 Vision, Meiji expects its pharmaceutical segment to bring operational income at a CAGR of 9%, and to reach over 30% in overseas sales ratio in FYE 3/2027. The firm said it will increase the sales of infectious disease products, generic drugs, and biopharmaceuticals in Japan and overseas with the goal of becoming the leading company in Asia in the infectious disease domain.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando
2024-11-26
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top